Aurinia Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.04.21	Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings (Businesswire)
15.03.21	Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report (Businesswire)
02.03.21	Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences (Businesswire)
24.02.21	Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights (Businesswire)
18.02.21	Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference (Businesswire)
17.02.21	Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021 (Businesswire)
31.01.21	Januar 2021: Die Expertenmeinungen zur Aurinia Pharmaceuticals-Aktie (finanzen.net)
23.01.21	FDA Approves Aurinia Pharma's Lupkynis - Second Lupus Nephritis Drug In A Month (RTTNews)
23.01.21	FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis (Businesswire)
22.01.21	Pre-market Movers In Healthcare Sector: ADMP, FLDM, ATOS, AUPH, SENS... (RTTNews)
11.01.21	Will Aurinia Pharma's Lupus Nephritis Drug Pass FDA Muster? (RTTNews)
08.01.21	Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences (Businesswire)
29.12.20	Biotech Stocks Facing FDA Decision In January 2021 (RTTNews)
17.12.20	Aurinia gibt Kooperations- und Lizenzvertrag mit Otsuka Pharmaceutical Co., Ltd. über die Entwicklung und Vermarktung von Voclosporin in Europa und Japan bekannt (Businesswire)
17.12.20	Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan (Businesswire)
15.12.20	Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity (Businesswire)
02.12.20	Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference (Businesswire)
20.11.20	Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
12.11.20	Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference (Businesswire)
10.11.20	Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights (Businesswire)
09.11.20	Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020 (Businesswire)
03.11.20	AUPH's Dry Eye Syndrome Study Fails, KPTI's SEAL Study Hits Goal, REGN Halts Rare Bone Disease Trial (RTTNews)
02.11.20	Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome (Businesswire)
28.10.20	AUPH Initiates VOCOVID Trial, KALA Gets FDA Nod, NVAX Expands COVID-19 Vaccine Study Size In UK (RTTNews)
27.10.20	Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19 (Businesswire)
22.10.20	Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020 (Businesswire)
14.10.20	Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com (Businesswire)
02.10.20	Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
28.09.20	Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome (Businesswire)
10.09.20	Aurinia Pharmaceuticals to Present at Three Upcoming Virtual Investor Conferences (Businesswire)
05.09.20	Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
11.08.20	Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights (Businesswire)
10.08.20	Ausblick: Aurinia Pharmaceuticals informiert über die jüngsten Quartalsergebnisse (finanzen.net)
04.08.20	Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference (Businesswire)
30.07.20	Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020 (Businesswire)
27.07.20	Aurinia Closes US$200 Million Public Offering of Common Shares (Businesswire)
23.07.20	Pre-market Movers In Healthcare Sector: ENTX, IMRN, CNTG, IMMP... (RTTNews)
23.07.20	Aurinia Prices US$200 Million Public Offering of Common Shares (Businesswire)
22.07.20	Aurinia Announces Public Offering of Common Shares (Businesswire)
22.07.20	Stock Alert: Aurinia Pharma Jumps 11% On Priority Review For Voclosporin (RTTNews)
22.07.20	AUPH Faces FDA In Jan, ARCT To Advance LUNAR-COV19 Vaccine, IFRX On Watch, All Eyes On ALEC (RTTNews)
21.07.20	Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis (Businesswire)
22.06.20	Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome (Businesswire)
05.06.20	Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress (Businesswire)
03.06.20	Aurinia Announces Results of Annual General Meeting (Businesswire)
01.06.20	Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (Businesswire)
26.05.20	Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis (Businesswire)
15.05.20	Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets’ Virtual Global Healthcare Conference (Businesswire)
14.05.20	Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights (Businesswire)
13.05.20	Ausblick: Aurinia Pharmaceuticals stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	137.35	1.40 %	K V
Sonova Hldg	297.30	1.29 %	K V
Logitech Intl	74.86	1.22 %	K V
Nestle	75.22	1.02 %	K V
Alcon	76.32	0.95 %	K V
UBS Group	28.17	-0.67 %	K V
Swiss Re	131.95	-0.68 %	K V
Geberit	533.80	-0.78 %	K V
Lonza Grp	541.40	-0.81 %	K V
Kuehne+Nagel Int	202.60	-1.65 %	K V

Nachrichten zu Aurinia Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten